Physician

Andy C Lin, M.D.

According to 2025 Medicare claims, Andy Lin, M.D. (NPI: 1336204031) practices cardiac electrophysiology in the Chicago-Naperville-Schaumburg, IL market, with the plurality of this provider's patient population coming from Cook, IL. This provider's primary affiliated billing organization is ADVANCED HEART GROUP SC (NPI: 1518945989; TIN: 364351282) and primary practice location at 60426-3558. Lin is affiliated with the UCMCNACO, LLC (ACO ID: A3531), participating under the MSSP model.

Lin's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,698 traditional Medicare patients, billed 9,709 HCPCS/CPT codes, and received $676,160 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 4,962 prescription claims across 713 beneficiaries totaling $1,273,938 in drug costs, led by Eliquis (Apixaban). 2023 DME data shows 33 claims. Open Payments data shows 28 records totaling $611. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $421,566 to $676,160. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $254,513 to $1,273,938. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $24,171 to $74,582.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,627	7,500	$421,566
2016	1,591	9,214	$473,139
2017	1,593	11,208	$581,559
2018	1,484	13,482	$646,397
2019	1,393	13,861	$677,594
2020	1,824	15,212	$752,561
2021	2,187	15,610	$787,605
2022	1,738	15,412	$725,921
2023	1,732	14,680	$681,804
2024	1,698	9,709	$676,160

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	349	2,464	$254,513
2016	399	2,615	$320,092
2017	449	3,053	$394,778
2018	465	3,335	$500,071
2019	527	3,658	$561,570
2020	628	4,309	$798,561
2021	655	4,508	$943,625
2022	642	4,136	$889,007
2023	666	4,170	$1,066,056
2024	713	4,962	$1,273,938

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	13	$24,164
2016	N/R	17	$33,155
2017	N/R	N/R	N/R
2018	N/R	12	$25,554
2019	N/R	N/R	N/R
2020	N/R	18	$40,642
2021	12	41	$88,954
2022	12	30	$68,121
2023	N/R	33	$74,582
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	511	1,066	$145
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	495	507	$117
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	545	1,058	$14
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	584	1,169	$12
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	849	1,029	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	479	33,760	$648,522
Entresto	Sacubitril/Valsartan	117	8,368	$186,670
Camzyos	Mavacamten	13	365	$103,949
Xarelto	Rivaroxaban	72	5,160	$93,273
Multaq	Dronedarone Hcl	33	2,310	$60,080

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	28	$611	Boehringer Ingelheim Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Andy C. Lin, M.D.?

Tedicare shows public-source Medicare data for Andy C. Lin, M.D. (NPI 1336204031), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andy C. Lin, M.D. have ACO affiliation data?

Andy C. Lin, M.D. is shown with ACO affiliation data for UCMCNACO, LLC (MSSP, ACO ID A3531).

What billing organization is linked to Andy C. Lin, M.D.?

Andy C. Lin, M.D. is linked to ADVANCED HEART GROUP SC (billing NPI 1518945989) in the available physician profile data.

Does Andy C. Lin, M.D. have Open Payments data?

Andy C. Lin, M.D. has 28 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.